Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19-Reference-Cited by-同舟云学术

Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19

Published:2024-08-07 Issue: Volume: Page:
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Chang Ming,Chen Yizhe^ORCID,Ogasawara Ken^ORCID,Schmidt Brian James,Gaohua Lu^ORCID

Funder

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00280-024-04696-y.pdf

Reference21 articles.

1. Bristol Myers Squibb (2023) Inrebic® (fedratinib) prescribing information. https://packageinserts.bms.com/pi/pi_inrebic.pdf. Accessed 20 Mar 2024

2. European Medicines Agency Inrebic® (fedratinib) [summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb (2024) https://www.ema.europa.eu/en/documents/product-information/inrebic-epar-product-information_en.pdf. Accessed 20 Mar 2024

3. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29(7):789–796. https://doi.org/10.1200/JCO.2010.32.8021

4. Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, Xu C, Cao H, Talpaz M (2015) A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J 5(8):e335. https://doi.org/10.1038/bcj.2015.63

5. Ogasawara K, Zhou S, Krishna G, Palmisano M, Li Y (2019) Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia. Cancer Chemother Pharmacol 84(4):891–898. https://doi.org/10.1007/s00280-019-03929-9